New CXXC5/DVL interaction inhibitors disclosed in CK Regeon patent
Sep. 20, 2024
CK Regeon Inc. has divulged indirubin derivatives acting as CXXC-type zinc finger protein 5 (CXXC5)/DVL interaction inhibitors reported to be useful for the treatment of skin lesions, wounds, neurodegeneration, metabolic disorders and bone disorders.